Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by forhandlarenon Sep 08, 2022 12:56am
286 Views
Post# 34948584

Positive sentiment in the works

Positive sentiment in the worksI read that some investors blow of some steam here, which can be healthy from time to time - but don't get stuck in the mud!

Trust me, I know the fealing that my investments seems to be locked in this company because of false expectations that brought me there, low volume and low share price.

But sometime one need to realize that bashing will scare off new investors - the very same investors the we all rely on to propel the share price...

I think that the Abbvie deal is good enough considering upfront, milestones, royalty and manufacturing. But don't expect it to be fantastic - I save that for the upcoming anti-aging deal.

They came to the table from a weak position (in need of the deal to move the company forward, weak R+F deal), but on the other hand they had Linda Pullan in the negotiating team and Abbvie really wanted to close the deal because they knew the details if the clinical trial.

The big picture is important now. A new chapter is about to be written and the results presented within 3-4 months.

Seems like a new CEO is in the works among other various corporate developments. Announcement of anti-aging partner and start of the clinical trial. Another shot on anti-viral. Diabetes pet deal. Clarification of the new indication where I put my bets on obesity.

We should be very close to a point where everyone who wants to exit would be able to do so with a healthy profit. So let's turn the tide into a more positive sentiment!
<< Previous
Bullboard Posts
Next >>